MicroRNA-891a-5p is a novel biomarker for non-small cell lung cancer and targets HOXA5 to regulate tumor cell biological function.
HOXA5
biological function
clinical significance
miR-891a-5p
non-small cell lung cancer
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
02
09
2020
accepted:
23
02
2021
entrez:
14
5
2021
pubmed:
15
5
2021
medline:
15
5
2021
Statut:
ppublish
Résumé
Numerous studies have shown that the dysregulation of microRNA (miRNA/miR) is an important factor in the pathogenesis of lung cancer. However, the role of miR-891a-5p in non-small cell lung cancer (NSCLC) remains unclear. Therefore, the present study aimed to examine the clinical value and biological function of miR-891a-5p in NSCLC. The mRNA expression level of miR-891a-5p in NSCLC was determined using reverse transcription-quantitative PCR and was used to determine the diagnostic value of miR-891a-5p, by creating a receiver operating characteristic curve. Kaplan-Meier and Cox regression analyses were used to evaluate its prognostic value in patients with NSCLC. Furthermore, cell experiments were performed to investigate the underlying mechanisms and functional role of miR-891a-5p in NSCLC progression. The results indicated that miR-891a-5p expression level was significantly higher in serum and tissues from patients with NSCLC and NSCLC cell lines. In addition, serum miR-891a-5p was found to have a diagnostic value in patients with NSCLC, and the increase in the expression level of miR-891a-5p in tumor tissues was associated with differentiation, and the tumor, node and metastases stages of cancer, which could be used for NSCLC prognosis. In addition, the experiments revealed that NSCLC cell proliferation, invasion and migration were significantly increased by the overexpression of miR-891a-5p and were significantly reduced by its downregulation. Furthermore, a luciferase reporter assay and the protein expression levels of HOXA5 showed that HOXA5 might be a miR-891a-5p target gene. In summary, the results indicated that high miR-891a-5p expression level could be a novel biomarker in patients with NSCLC and that it promoted tumor cell proliferation, invasion and migration. HOXA5 may be a target of miR-891a-5p, which may mediate miR-891a-5p function in NSCLC.
Identifiants
pubmed: 33986868
doi: 10.3892/ol.2021.12768
pii: OL-0-0-12768
pmc: PMC8114465
doi:
Types de publication
Journal Article
Langues
eng
Pagination
507Informations de copyright
Copyright: © Wan et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):5964-5971
pubmed: 30280778
Drug Discov Today. 2017 Feb;22(2):424-432
pubmed: 27815139
Front Oncol. 2019 May 21;9:394
pubmed: 31165042
Oncol Rep. 2016 Oct;36(4):2101-7
pubmed: 27513319
Onco Targets Ther. 2016 Sep 15;9:5679-5692
pubmed: 27695346
Diagn Pathol. 2019 Oct 24;14(1):117
pubmed: 31651329
Gene. 2019 Jan 10;681:62-68
pubmed: 30267809
BMC Med Res Methodol. 2017 Apr 7;17(1):53
pubmed: 28388943
Cell Physiol Biochem. 2018;45(3):1023-1033
pubmed: 29439250
Cancer Treat Res. 2016;170:47-75
pubmed: 27535389
Cancer Biomark. 2019;24(3):279-289
pubmed: 30883341
J Cancer. 2020 Apr 6;11(13):3771-3782
pubmed: 32328182
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
BMC Cancer. 2012 Aug 09;12:348
pubmed: 22876840
Oncol Rep. 2019 Mar;41(3):1638-1648
pubmed: 30592286
BMC Med Genomics. 2020 Jan 6;13(1):3
pubmed: 31906958
J Cancer. 2017 Apr 9;8(6):1071-1081
pubmed: 28529621
Carcinogenesis. 2010 Apr;31(4):559-66
pubmed: 20053927
Clin Lab. 2015;61(1-2):187-90
pubmed: 25807655
PET Clin. 2018 Jan;13(1):1-10
pubmed: 29157380
Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819882949
pubmed: 31672084
Cancer Sci. 2018 Feb;109(2):289-296
pubmed: 29161765
Int J Cancer. 2013 Jun 15;132(12):2884-93
pubmed: 23225545
Cell Death Dis. 2018 Sep 6;9(9):912
pubmed: 30190481
Nucleic Acids Res. 2019 Mar 18;47(5):2700
pubmed: 30726947
Chin Med J (Engl). 2013;126(24):4624-8
pubmed: 24342300
Int Rev Cell Mol Biol. 2017;333:229-268
pubmed: 28729026
Nat Rev Cancer. 2014 Aug;14(8):535-46
pubmed: 25056707
Bratisl Lek Listy. 2018;119(1):60-65
pubmed: 29405733
Cancer Cell. 2015 Dec 14;28(6):815-829
pubmed: 26678341
Int J Clin Exp Pathol. 2019 Jul 01;12(7):2496-2505
pubmed: 31934076
PLoS One. 2017 Feb 15;12(2):e0171751
pubmed: 28199399
Mol Med Rep. 2015 Mar;11(3):2034-40
pubmed: 25376560
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Med Clin North Am. 2019 May;103(3):463-473
pubmed: 30955514
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Eur Rev Med Pharmacol Sci. 2020 Jan;24(2):712-720
pubmed: 32016973
Trends Biochem Sci. 2012 Nov;37(11):460-5
pubmed: 22944280